her2 kinase assay kit Search Results


humanized anti erbb2 monoclonal antibody herceptin  (Rockland Immunochemicals)
90
Rockland Immunochemicals humanized anti erbb2 monoclonal antibody herceptin
Humanized Anti Erbb2 Monoclonal Antibody Herceptin, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/her2+kinase+assay+kit/pm18654610-23-30-66?v=Rockland+Immunochemicals
Average 90 stars, based on 1 article reviews
humanized anti erbb2 monoclonal antibody herceptin - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
her2 kinase assay kit  (BPS Bioscience)
94
BPS Bioscience her2 kinase assay kit
Protein-ligand docking of known kinase inhibitors. (a) Predicted binding pose of AQ4 (erlotinib) to EGFR (green), in comparison with experimental binding pose from 4hjo (red). (b) Binding pose prediction based on protein-ligand docking of 03P with <t>HER2</t> kinase (3rcd, green), in comparison with experimentally derived binding pose (red).
Her2 Kinase Assay Kit, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/her2+kinase+assay+kit/pmc10765126-40-9-19?v=BPS+Bioscience
Average 94 stars, based on 1 article reviews
her2 kinase assay kit - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
receptor tyrosine-protein kinase erbb-2 (her2) alphalisa detection kit, 500 assay points  (PerkinElmer)
N/A
The AlphaLISA® Human epidermal growth factor receptor 2 (ErbB-2, NEU, or HER2) Detection Kit is designed for detection and quantitation of human ErbB-2 in serum, buffered solution or cell culture medium in a homogeneous (no-wash
   Buy from Supplier

Image Search Results


Protein-ligand docking of known kinase inhibitors. (a) Predicted binding pose of AQ4 (erlotinib) to EGFR (green), in comparison with experimental binding pose from 4hjo (red). (b) Binding pose prediction based on protein-ligand docking of 03P with HER2 kinase (3rcd, green), in comparison with experimentally derived binding pose (red).

Journal: Oncology Research

Article Title: High-throughput computational screening and in vitro evaluation identifies 5-(4-oxo-4H-3,1-benzoxazin-2-yl)-2-[3-(4-oxo-4H-3,1-benzoxazin-2-yl) phenyl]-1H-isoindole-1,3(2H)-dione (C3), as a novel EGFR—HER2 dual inhibitor in gastric tumors

doi: 10.32604/or.2023.043139

Figure Lengend Snippet: Protein-ligand docking of known kinase inhibitors. (a) Predicted binding pose of AQ4 (erlotinib) to EGFR (green), in comparison with experimental binding pose from 4hjo (red). (b) Binding pose prediction based on protein-ligand docking of 03P with HER2 kinase (3rcd, green), in comparison with experimentally derived binding pose (red).

Article Snippet: EGFR (T790M/L858R) Kinase Assay Kit (Catalog # 40322) and HER2 Kinase Assay Kit (Catalog # 40721) were purchased from BPS Bioscience, SD, USA.

Techniques: Binding Assay, Comparison, Derivative Assay

High-throughput virtual screening identify targeted compounds for EGFR and HER2. (a) Predicted binding scores for the ChemBridge compounds against EGFR kinase. Histogram includes compounds having docking score >2 standard deviation from the mean docking scores (−9.7 kcal/mol). (b) Docking scores, >2 standard deviation from the mean, for top EGFR compounds from (a) screened against HER2 kinase. (c) Predicted docking score for compound C3 and a known inhibitor AQ4 against EGFR. (d) Predicted docking score for compound C3 and a known inhibitor 03P against HER2. (e) Interacting residues between compound C3 and EGFR. (f) 2D representation of compound C3 interactions at the kinase site of EGFR. (g) Interacting residues between compound C3 and HER2. (h) 2D representation of compound C3 interactions at the kinase site of HER2.

Journal: Oncology Research

Article Title: High-throughput computational screening and in vitro evaluation identifies 5-(4-oxo-4H-3,1-benzoxazin-2-yl)-2-[3-(4-oxo-4H-3,1-benzoxazin-2-yl) phenyl]-1H-isoindole-1,3(2H)-dione (C3), as a novel EGFR—HER2 dual inhibitor in gastric tumors

doi: 10.32604/or.2023.043139

Figure Lengend Snippet: High-throughput virtual screening identify targeted compounds for EGFR and HER2. (a) Predicted binding scores for the ChemBridge compounds against EGFR kinase. Histogram includes compounds having docking score >2 standard deviation from the mean docking scores (−9.7 kcal/mol). (b) Docking scores, >2 standard deviation from the mean, for top EGFR compounds from (a) screened against HER2 kinase. (c) Predicted docking score for compound C3 and a known inhibitor AQ4 against EGFR. (d) Predicted docking score for compound C3 and a known inhibitor 03P against HER2. (e) Interacting residues between compound C3 and EGFR. (f) 2D representation of compound C3 interactions at the kinase site of EGFR. (g) Interacting residues between compound C3 and HER2. (h) 2D representation of compound C3 interactions at the kinase site of HER2.

Article Snippet: EGFR (T790M/L858R) Kinase Assay Kit (Catalog # 40322) and HER2 Kinase Assay Kit (Catalog # 40721) were purchased from BPS Bioscience, SD, USA.

Techniques: High Throughput Screening Assay, Binding Assay, Standard Deviation

Molecular dynamics simulation of the HER2-C3 complex (a) Snapshot of trajectories taken at different time points during the simulation. (b) Predicted ligand root mean square deviation of compound C3 when bound to HER2. (c) Predicted average hydrogen bonds between compound C3 and HER2 for a 100 ns simulation.

Journal: Oncology Research

Article Title: High-throughput computational screening and in vitro evaluation identifies 5-(4-oxo-4H-3,1-benzoxazin-2-yl)-2-[3-(4-oxo-4H-3,1-benzoxazin-2-yl) phenyl]-1H-isoindole-1,3(2H)-dione (C3), as a novel EGFR—HER2 dual inhibitor in gastric tumors

doi: 10.32604/or.2023.043139

Figure Lengend Snippet: Molecular dynamics simulation of the HER2-C3 complex (a) Snapshot of trajectories taken at different time points during the simulation. (b) Predicted ligand root mean square deviation of compound C3 when bound to HER2. (c) Predicted average hydrogen bonds between compound C3 and HER2 for a 100 ns simulation.

Article Snippet: EGFR (T790M/L858R) Kinase Assay Kit (Catalog # 40322) and HER2 Kinase Assay Kit (Catalog # 40721) were purchased from BPS Bioscience, SD, USA.

Techniques:

MM/PBSA-based binding free energy predictions for compound C3 (a) Predicted binding free energy (ΔG binding ) for compound C3 to EGFR and HER2 calculated based on MM/PBSA scoring from simulation trajectories (total cutoff value: −63.59 kJ/mol for EGFR and −87.42 kJ/mol for HER2). (b) Residue level binding energy contribution for the EGFR-C3 complex (cut off value −6 kJ/mol). (c) Residue level binding energy contribution for the HER2-C3 complex (cutoff value −6 kJ/mol). (d) MD simulation and MM/PBSA-based predicted binding free energy comparison between compound C3 and dacomitinib bound to EGFR (e) MD simulation and MM/PBSA-based predicted binding free energy comparison between compound C3 and dacomitinib bound to HER2.

Journal: Oncology Research

Article Title: High-throughput computational screening and in vitro evaluation identifies 5-(4-oxo-4H-3,1-benzoxazin-2-yl)-2-[3-(4-oxo-4H-3,1-benzoxazin-2-yl) phenyl]-1H-isoindole-1,3(2H)-dione (C3), as a novel EGFR—HER2 dual inhibitor in gastric tumors

doi: 10.32604/or.2023.043139

Figure Lengend Snippet: MM/PBSA-based binding free energy predictions for compound C3 (a) Predicted binding free energy (ΔG binding ) for compound C3 to EGFR and HER2 calculated based on MM/PBSA scoring from simulation trajectories (total cutoff value: −63.59 kJ/mol for EGFR and −87.42 kJ/mol for HER2). (b) Residue level binding energy contribution for the EGFR-C3 complex (cut off value −6 kJ/mol). (c) Residue level binding energy contribution for the HER2-C3 complex (cutoff value −6 kJ/mol). (d) MD simulation and MM/PBSA-based predicted binding free energy comparison between compound C3 and dacomitinib bound to EGFR (e) MD simulation and MM/PBSA-based predicted binding free energy comparison between compound C3 and dacomitinib bound to HER2.

Article Snippet: EGFR (T790M/L858R) Kinase Assay Kit (Catalog # 40322) and HER2 Kinase Assay Kit (Catalog # 40721) were purchased from BPS Bioscience, SD, USA.

Techniques: Binding Assay, Residue, Comparison

IC 50 of C3 against (a) EGFR and (b) HER2 enzymes. GI 50 of C3 in controlling proliferation of (c) KATO III and (d) SNU-5 cells.

Journal: Oncology Research

Article Title: High-throughput computational screening and in vitro evaluation identifies 5-(4-oxo-4H-3,1-benzoxazin-2-yl)-2-[3-(4-oxo-4H-3,1-benzoxazin-2-yl) phenyl]-1H-isoindole-1,3(2H)-dione (C3), as a novel EGFR—HER2 dual inhibitor in gastric tumors

doi: 10.32604/or.2023.043139

Figure Lengend Snippet: IC 50 of C3 against (a) EGFR and (b) HER2 enzymes. GI 50 of C3 in controlling proliferation of (c) KATO III and (d) SNU-5 cells.

Article Snippet: EGFR (T790M/L858R) Kinase Assay Kit (Catalog # 40322) and HER2 Kinase Assay Kit (Catalog # 40721) were purchased from BPS Bioscience, SD, USA.

Techniques: